Featured Oct 1, 2024 press release Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer Oct 1, 2024 press release Read More → Oct 1, 2024 press release May 2, 2024 press release Luxa Biotechnology Receives $4 Million Grant for Clinical Trial of Dry AMD Treatment May 2, 2024 press release Read More → May 2, 2024 press release Jan 23, 2024 press release Luxa Biotechnology announces paper on 'Identification of Biomarkers for Diversity and Transplantation Efficacy of Retinal Pigment Epithelial Cells' by Dr. Sally Temple. Jan 23, 2024 press release Read More → Jan 23, 2024 press release Jan 23, 2024 press release Luxa Biotechnology to Provide Update on Clinical Trial of Retinal Pigmented Epithelium Stem Cell (RPESC) Technology for Treatment of Dry Age-Related Macular Degeneration in Panel Session at ARVO Jan 23, 2024 press release Read More → Jan 23, 2024 press release Jan 23, 2024 press release The Report of the Annual Meeting hosted by the National Eye Institute in the United States has been released Jan 23, 2024 press release Read More → Jan 23, 2024 press release Jan 23, 2024 press release Sally Temple, Ph.D., named to National Academy of Medicine Jan 23, 2024 press release Read More → Jan 23, 2024 press release Jan 23, 2024 press release Luxa Biotechnology gives first dose to patients in clinical trial Jan 23, 2024 press release Read More → Jan 23, 2024 press release
